Neuroleptic malignant syndromeMANAGEMENT

PSYCHIATRIC PRESENTATIONS · 12 SECTIONS

⚲

468 items

☷ Legend

⚲

Cardiovascular Presentations66▾

Respiratory Presentations47▾

Neurological Presentations77▾

Gastrointestinal Presentations63▾

Genitourinary and Reproductive Presentations44▾

Infectious Disease Presentations146▾

Trauma Presentations88▾

Toxicologic Presentations67▾

Psychiatric Presentations25▾

Acute anxiety Acute psychosis Agitation:behavioral emergency Anorexia Nervosa (Medical Complications)Bipolar disorder Bipolar Disorder (Depressive Episode)Bipolar Disorder (Manic Episode)Bulimia Nervosa (Medical Complications)Catatonia Conversion disorder Factitious Disorder Failure to Cope (Social)Failure to Thrive Generalized Anxiety Disorder Homicidal Ideation Major Depressive Disorder Major depressive episode Malingering Neuroleptic malignant syndrome Panic Attack Post-Traumatic Stress Disorder (Acute)Schizophrenia Exacerbation Suicidal Ideation Suicidal ideation and attempt Suicide Attempt

Musculoskeletal and Rheumatologic Presentations89▾

Dermatology Presentations21▾

Environmental and Exposure Presentations26▾

Hematologic and Oncologic Presentations30▾

Pediatric-Specific Presentations13▾

Endocrine and Metabolic Presentations42▾

ENT and Maxillofacial Presentations21▾

Ophthalmologic Presentations15▾

Obstetric Presentations17▾

Systemic and Miscellaneous Presentations15▾

01Approach to the Critical Patient/attcp49

Immediate stabilization

›Time critical priorities

›Offending agents held immediately

›Dopamine receptor antagonists stopped

›Dopaminergic agents restarted if withdrawal trigger

›Airway and ventilation

›Aspiration risk with hypersalivation and obtundation

›Neuromuscular rigidity contributing to respiratory failure

›Temperature control

›Active external cooling

›Antipyretics not reliable for hyperthermia physiology

›Circulation and perfusion

›Isotonic crystalloid for hypovolemia from diaphoresis

›Vasopressor support for persistent shock after fluids

Monitoring and early actions

›Monitoring bundle

›Core temperature monitoring

›Rectal or esophageal probe for severe hyperthermia

›Trend every 15-30 minutes during active cooling

›Cardiorespiratory monitoring

›Continuous ECG for dysrhythmia risk

›Continuous pulse oximetry

›Urine output monitoring

›Foley for rhabdomyolysis risk and immobility

›Target urine output 1-2 ml/kg/hour if rhabdomyolysis

›Sedation strategy

›Benzodiazepines preferred for agitation and rigidity

›Avoid antipsychotics for agitation control

Key decision points

›Diagnostic pivot points

›Hyperthermia with rigidity plus dopamine antagonist exposure

›Neuroleptic malignant syndrome favored

›Early presentations without fever possible

›Clonus and hyperreflexia

›Serotonin syndrome favored

›NMS less likely without lead pipe rigidity

›Recent anesthesia with succinylcholine or volatile agent

›Malignant hyperthermia favored

›Rapid onset minutes to hours

Consultation triggers

›Team activation

›ICU consultation

›Any hyperthermia with rigidity and altered mental status

›Rising creatine kinase or end organ dysfunction

›Toxicology consultation

›Polypharmacy or unclear toxidrome

›Guidance on dantrolene or dopaminergic therapy

›Psychiatry consultation

›Malignant catatonia overlap

›Reintroduction plan for antipsychotic therapy

›Neurology consultation

›Parkinsonism hyperpyrexia syndrome concern

›Alternative neurologic diagnoses on exam

02History/hx36

Exposure and timeline

›Medication and withdrawal context

›Dopamine receptor antagonist exposure

›Antipsychotics

›Antiemetics with D2 blockade

›Dopaminergic medication changes

›Levodopa reduction or stoppage

›Dopamine agonist stoppage

›Dose and route

›Recent initiation or rapid up titration

›Parenteral dosing or long acting depot injection

›Time course

›Typical evolution over 1-3 days

›Onset usually within first month of exposure

Risk modifiers

›Predisposing factors

›Prior episode of NMS

›Recurrence risk with re exposure

›Documentation of culprit agent and circumstances

›Concomitant medications

›Lithium coadministration

›Multiple antidopaminergic agents

›Physiologic stressors

›Dehydration

›Infection or systemic inflammation

›Neurologic vulnerability

›Parkinson disease

›Lewy body dementia

Symptom pattern

›Core symptom sequence

›Mental status changes

›Agitation then stupor or mutism

›Catatonic features

›Extrapyramidal symptoms

›Lead pipe rigidity

›Tremor or dystonia

›Autonomic instability

›Diaphoresis

›Labile blood pressure and tachycardia

03Physical Exam/exam43

Core findings

›Syndrome defining features

›Temperature and diaphoresis

›Hyperthermia commonly above 38 C

›Profuse sweating and warm skin

›Neuromuscular tone

›Generalized rigidity

›Lead pipe resistance throughout range of motion

›Mental status

›Delirium

›Stupor or coma

›Autonomic signs

›Sinus tachycardia

›Labile hypertension or hypotension

Focused bedside differentiation

›Exam discriminators

›Reflexes and clonus

›Hyperreflexia and inducible clonus suggest serotonin syndrome

›Normal reflexes with rigidity suggest NMS

›Pupils and mucosa

›Mydriasis and dry mucosa suggest anticholinergic toxidrome

›Diaphoresis argues against pure anticholinergic state

›Muscle tone pattern

›Rigidity without clonus suggests NMS

›Tremor plus clonus suggests serotonin syndrome

Complication screen

›End organ threat findings

›Respiratory status

›Hypoventilation from rigidity

›Aspiration signs

›Volume status

›Dehydration from diaphoresis

›Shock physiology

›Renal and rhabdomyolysis clues

›Dark urine

›Muscle tenderness

PITFALLS

›Common misses

›Early NMS without high fever

›Mental status change plus rigidity preceding hyperthermia

›Creatine kinase may be normal early

›Malignant catatonia mimic

›Behavioral prodrome weeks

›Waxy flexibility and stereotypies

›Sepsis anchoring

›Infection workup still required

›Medication history remains decisive

04Differential Diagnosis/ddx39

Hyperthermia with altered mental status

›Life threatening alternatives

›Sepsis and meningoencephalitis

›Fever with leukocytosis and shock

›Focal neurologic deficits or meningismus

›Heat stroke

›Environmental exposure

›Hot dry skin possible

›Thyroid storm

›Hyperthyroid history

›Tremor without lead pipe rigidity

Medication and toxidrome mimics

›Toxicologic differentials

›Serotonin syndrome

›Serotonergic exposure

›Clonus and hyperreflexia

›Malignant hyperthermia

›Triggering anesthetics or succinylcholine

›Very rapid onset

›Sympathomimetic intoxication

›Agitation and hyperthermia

›Diaphoresis and mydriasis

›Anticholinergic toxicity

›Dry skin and urinary retention

›Ileus and mydriasis

›Sedative hypnotic or alcohol withdrawal

›Tremor and agitation

›Autonomic hyperactivity

Neurologic causes

›Primary neurologic processes

›Nonconvulsive status epilepticus

›Persistent altered mental status

›EEG responsive state

›Stroke involving basal ganglia or brainstem

›Focal deficits

›Sudden onset

›Autoimmune encephalitis

›Psychiatric symptoms then dysautonomia

›Catatonia overlap

Coding alignment

›Coding references

›ICD-10 G21.0 Neuroleptic malignant syndrome

›SNOMED CT Neuroleptic malignant syndrome concept

05Laboratory Tests/lt53

Core severity labs

›Baseline panel

›Creatine kinase for rhabdomyolysis severity

›Marked elevation often above 1000 U/L

›Trend every 6-12 hours until falling

›Basic metabolic profile

›Potassium mmol/l for hyperkalemia risk

›Creatinine micromol/l for AKI risk

›Liver enzymes

›AST and ALT elevation from muscle injury or hepatic stress

›Bilirubin for hepatic dysfunction screen

›Complete blood count

›Leukocytosis supportive but nonspecific

›Platelets for DIC screen

Perfusion and acid base

›Metabolic status

›Lactate mmol/l

›Elevated with shock or severe hyperthermia

›Serial trend for resuscitation response

›Venous or arterial blood gas

›pH for acidemia

›PaCO2 mmHg for hypoventilation

›Serum glucose mmol/l

›Stress hyperglycemia

›Hypoglycemia exclusion

Renal and pigment nephropathy

›Rhabdomyolysis complications

›Urinalysis

›Heme positive with few RBCs consistent with myoglobin

›Specific gravity for dehydration

›Urine myoglobin where available

›Supports pigment nephropathy

›Absence does not exclude

Infection evaluation

›Infection rule out set

›Blood cultures times two before antibiotics when sepsis possible

›Do not delay NMS therapy for culture collection

›Broad spectrum antibiotics when septic shock physiology

›Urine culture when urinary source possible

›Dysuria history or catheter related concern

›Pyuria and bacteriuria correlation

›CRP or ESR

›Inflammatory marker elevation nonspecific

›Trend may support infection control response

Toxicology and endocrine

›Alternative drivers

›Serum acetaminophen concentration if overdose possible

›Early testing even without history

›Coingestion risk with psychiatric presentations

›Serum salicylate concentration if acid base pattern suggests

›Mixed respiratory alkalosis and metabolic acidosis

›Tinnitus or vomiting

›TSH and free T4 if thyroid storm possible

›Tremor and hyperthermia differential

›Tachyarrhythmia disproportionate

›Serum lithium if exposure possible

›Neurotoxicity overlap

›AKI increases toxicity risk

06Diagnostic Tests/dt49

Scoring Systems

›Diagnostic frameworks

›International expert consensus criteria

›Point based criteria with weighted features

›Threshold score 74 out of 100 supporting diagnosis

›Levenson criteria

›Major features

›Fever

›Rigidity

›Elevated creatine kinase

›Minor features

›Tachycardia

›Abnormal blood pressure

›Tachypnea

›Altered consciousness

›Diaphoresis

›Leukocytosis

›Diagnostic combinations

›Three major features

›Two major plus four minor features

›Clinical diagnosis principle

›No single laboratory test confirms NMS

›Medication exposure plus characteristic exam remains central

MRI

›MRI indications

›Brain MRI for alternative neurologic diagnosis

›Basal ganglia stroke concern

›Autoimmune encephalitis concern

›Spine MRI when rigidity source unclear

›Spinal epidural abscess differential

›Severe focal back pain or neurologic deficits

›CT indications

›Noncontrast CT head

›Focal neurologic deficit

›New seizure or trauma

›CT chest for aspiration or pneumonia complications

›Hypoxia with abnormal chest radiograph

›Persistent fever with pulmonary signs

›CT pulmonary angiography

›Unexplained hypoxia plus VTE risk from immobility

›Sudden hemodynamic collapse

Ultrasound

›Ultrasound applications

›Point of care cardiac ultrasound

›Volume status and cardiac function

›Stress cardiomyopathy screening in shock

›Lung ultrasound

›Aspiration pneumonitis patterns

›Pulmonary edema evaluation

›Lower extremity venous ultrasound

›DVT evaluation with immobility

›Unilateral leg swelling

07Disposition/dispo17

Level of care

›Disposition targets

›ICU admission

›Hyperthermia with rigidity and altered mental status

›Creatine kinase rising or end organ injury

›Stepdown admission

›Resolving symptoms with stable vitals

›Downtrending creatine kinase and stable renal function

›Floor admission

›Mild presentation without hyperthermia and without organ dysfunction

›Reliable monitoring capacity and rapid escalation pathway

Transfer and follow up

›Transfer considerations

›Facility without ICU capability

›Early transfer before multiorgan failure

›Transport with active cooling and sedation plan

›Psychiatric placement

›Deferred until medically cleared

›Clear documentation of NMS episode and triggers

08Treatment/t77

Core management

›Supportive care foundation

›Offending agents discontinued

›All antipsychotics stopped

›D2 blocking antiemetics stopped

›Dopaminergic agents reinstated when withdrawal trigger

›Levodopa resumed promptly

›Dopamine agonist resumed promptly

›Cooling measures

›Evaporative cooling

›Ice packs to groin and axilla

›IV fluids and renal protection

›Isotonic crystalloid

›Urine output target 1-2 ml/kg/hour when rhabdomyolysis

›Sedation for agitation and rigidity

›Lorazepam IV 1-2 mg every 10-20 minutes as needed

›Diazepam IV 5-10 mg every 10-15 minutes as needed

Targeted pharmacotherapy

›Dopaminergic and muscle directed therapy

›Bromocriptine enteral

›Starting dose 2.5 mg by mouth every 8 hours

›Titrate to 5-10 mg every 6-8 hours if inadequate response

›Maximum 40 mg per day

›Continuation strategy

›Continue about 10 days after clinical resolution to reduce recurrence

›Gradual taper rather than abrupt stop

›Evidence level ACEP Level C

›Case series and expert consensus support

›Use in severe or refractory cases

›Amantadine enteral

›Initial dose 100 mg by mouth twice daily

›Titrate to 200 mg by mouth twice daily as needed

›Taper over days to weeks after stabilization

›Renal adjustment for reduced GFR

›GFR 30-50 ml/min dosing reduction

›GFR 15-30 ml/min dosing reduction

›Evidence level ACEP Level C

›Alternative when bromocriptine contraindicated

›Consider combination with bromocriptine in refractory disease

›Dantrolene IV

›Dose range 1-2.5 mg/kg IV every 6-8 hours

›Reasonable initial dose 1 mg/kg IV then reassess

›Maximum daily dose 10 mg/kg per day

›Safety considerations

›Avoid non dihydropyridine calcium channel blockers during therapy

›Hepatic dysfunction increases risk of prolonged effect

›Evidence level ACEP Level C

›Adjunct to supportive care

›Avoid monotherapy approach

Dysautonomia and complications

›Complication directed care

›Hypertension and tachycardia

›Short acting agents preferred

›Esmolol infusion titrated to heart rate control when needed

›Nicardipine infusion titrated to blood pressure control when needed

›Avoid long acting agents during labile course

›Rebound hypotension risk

›Delayed titration risk

›Hyperkalemia from rhabdomyolysis

›Calcium gluconate IV for ECG changes

›Insulin plus dextrose for intracellular shift

›Acute kidney injury

›Volume resuscitation guided by perfusion

›Renal replacement therapy for refractory hyperkalemia or acidosis

›VTE prevention

›Pharmacologic prophylaxis unless contraindicated

›Early mobilization when safe

›Aspiration risk management

›Head of bed elevation

›Early speech and swallow evaluation after stabilization

Refractory syndromes

›Escalation options

›ECT consideration

›Persistent malignant catatonia features

›Refractory course despite supportive care and pharmacotherapy

›Deep sedation and paralysis

›Severe hyperthermia not controlled with external cooling

›Rigidity causing ventilatory failure

›Evidence level ACEP Level C

›Reserved for severe and refractory disease

›Multidisciplinary decision making

09Special Populations/sp30

Pregnancy

›Pregnancy considerations

›Maternal stabilization priority

›Aggressive cooling and perfusion support

›Continuous fetal monitoring when viable gestation and feasible

›Medication safety

›Bromocriptine risk benefit discussion with obstetrics

›Dantrolene use reserved for severe disease

›Obstetric consultation

›Preterm labor monitoring during hyperthermia

›Delivery planning only after maternal stabilization

Geriatric

›Older adult considerations

›Atypical presentations

›Lower peak fever possible

›Higher baseline rigidity or parkinsonism confounders

›Medication vulnerability

›Polypharmacy increases diagnostic uncertainty

›Higher risk of aspiration and delirium

›Dosing and monitoring

›Slower titration of sedatives

›Close renal function monitoring for rhabdomyolysis

Pediatrics

›Pediatric considerations

›Weight based dosing

›Dantrolene mg/kg dosing strict

›Fluid resuscitation weight based

›Diagnostic pitfalls

›Viral illness confounding fever evaluation

›Developmental baseline affecting mental status assessment

›Consultation

›Pediatric ICU early involvement

›Pediatric toxicology input for adjunct therapies

10Background/b33

Epidemiology

›Population patterns

›Incidence in exposed patients

›Reported range about 0.01 percent to 3.2 percent depending on era and definition

›Declining incidence with newer antipsychotics and awareness

›Timing after exposure

›Highest risk after initiation or dose increase

›Most cases occur within first month of therapy

›Mortality

›Modern mortality commonly around 10 percent with early recognition and ICU care

›Death drivers include rhabdomyolysis and respiratory failure

Pathophysiology

›Mechanisms

›Central dopamine blockade

›D2 receptor blockade reduces hypothalamic thermoregulation control

›Nigrostriatal blockade contributes to rigidity

›Sympathetic dysregulation

›Autonomic instability with catecholamine excess features

›Labile blood pressure and tachyarrhythmias

›Skeletal muscle heat production

›Sustained contraction generates hyperthermia

›Rhabdomyolysis leads to pigment nephropathy

Therapeutic Considerations

›Treatment rationale

›Supportive care as cornerstone

›Cooling reduces enzymatic injury and organ failure risk

›Hydration reduces AKI risk from myoglobin

›Dopaminergic restoration

›Bromocriptine counteracts dopamine blockade

›Amantadine increases dopamine availability and reduces NMDA activity

›Muscle relaxation adjunct

›Dantrolene reduces calcium release in skeletal muscle

›Benefit uncertain and reserved for selected severe cases

›Evidence grading

›Most adjunct pharmacotherapy supported by case series and expert consensus

›Randomized controlled trial data limited by rarity

11Patient Discharge Instructions/pdi16

copy discharge instructions

›Discharge instructions

›This condition can worsen quickly

›Return immediately for fever

›Return immediately for confusion or severe sleepiness

›Movement and muscle symptoms

›Return immediately for severe stiffness

›Return immediately for dark urine or very low urine output

›Heart and breathing symptoms

›Return immediately for chest pain

›Return immediately for shortness of breath

›Medication safety

›Do not restart antipsychotic or nausea medications without clinician guidance

›Bring a complete medication list to follow up

›Follow up plan

›Follow up with prescribing clinician within 24-72 hours after discharge if discharged

›Clear written note of suspected NMS episode for future care

12References/r26

Clinical Guidelines and Reviews

›Key sources

›Gurrera RJ et al 2011 international consensus study diagnostic criteria using Delphi method

›Weighted point based diagnostic framework

›Basis for later validation work

›Gurrera RJ et al 2017 validation of international consensus diagnostic criteria

›Performance assessment of point based criteria

›Supports standardized diagnosis approach

›Strawn JR et al 2007 review in Am J Psychiatry

›Clinical features and management overview

›Malignant catatonia overlap discussion

›Tse L et al 2015 clinically oriented review

›Epidemiology and treatment considerations

›Risk factors and differential diagnosis

›NCBI Bookshelf StatPearls Neuroleptic Malignant Syndrome updated resource

›Broad overview of causative agents and management

›Emphasis on supportive care and adjuncts

Evidence Based Sources

›Supporting literature

›Rosebush and Stewart 1991 adjunctive dantrolene and bromocriptine discussion

›Observational outcomes in treated cohorts

›Highlights uncertainty of incremental benefit

›Case series and toxicology reviews on bromocriptine and amantadine

›Dosing patterns for severe disease

›Recurrence prevention with taper strategies

›Critical care syntheses on NMS management pathways

›Hyperthermia and rhabdomyolysis complication focus

›ICU supportive care bundles

Learn More: Neuroleptic malignant syndrome→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed June 16, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.